Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. Academic Article uri icon

Overview

abstract

  • Distinct sphingolipid metabolism of AML with MDS-related changes defines unique sensitivity to nanoliposomal C6-ceramide. Vinblastine alters sphingolipid metabolism to enhance the sensitivity of AML to nanoliposomal C6-ceramide.

publication date

  • September 10, 2019

Research

keywords

  • Ceramides
  • Drug Carriers
  • Leukemia, Myeloid, Acute
  • Liposomes
  • Sphingolipids

Identity

PubMed Central ID

  • PMC6737412

Scopus Document Identifier

  • 85072193038

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2018021295

PubMed ID

  • 31488436

Additional Document Info

volume

  • 3

issue

  • 17